FDA Approves New Cholesterol-Lowering Drug
Links shared publicly online about this topic.
- 1,815total visits
FDA Approves New Cholesterol-Lowering Drug
View full resource at medicalnewstoday.com
Tags: Cholesterol, Cholesterol Medication, Drug, FDA
Most Recently Shared on August 18, 2009 at 10:22 am By:
MedicalNewsToday: FDA Approves New Cholesterol-Lowering Drug http://bit.ly/2hLqoG Full http://bit.ly/gnORp
Report: FDA strengthens monitoring of post-approval drug safety
fda.gov — “A strengthened and modernized postmarket drug safety program has resulted in a substantial improvement in the U.S. Food and Drug Administration’s oversight of drugs once they reach the American public, according to a new report released today by the agency’s Center for Drug Evaluation and Research (CDER). The report, “Advances in FDA’s Safety Program for Marketed Drugs,” describes new scientific tools and enhanced capabilities that give the same priority to postmarket drug safety monitoring as t” View full resource at fda.gov
Most Recently Shared on April 21, 2012 at 8:42 pm By:
HealthTrendster Health Executive
Report: FDA strengthens monitoring of post-approval drug safety: A strengthened and… http://t.co/Nlax6RLR
FDA extends review of Qnexa diet pill for three more months – USATODAY.com
usatoday.com — “The decision on whether to approve the new diet drug won't be until about July 17, instead of April 17.” View full resource at usatoday.com
Most Recently Shared on April 9, 2012 at 11:11 pm By:
FDA will spend three more months reviewing Qnexa diet pill http://t.co/fsn0h53G
New diet drug Qnexa awaits FDA approval amid safety questions – USATODAY.com
usatoday.com — “Some experts say it could potentially help dieters lose about 10% of their weight, but with its former FDA rejection, how safe is it?” View full resource at usatoday.com
Most Recently Shared on April 4, 2012 at 11:02 pm By:
Diet drug Qnexa awaits FDA approval amid safety questions http://t.co/aMYJ6Ol8
New diet drug Qnexa awaits FDA approval amid safety questions – USATODAY.com
usatoday.com — “Some experts say it could potentially help dieters lose about 10% of their weight, but with its former FDA rejection, how safe is it?” View full resource at usatoday.com
Most Recently Shared on April 4, 2012 at 10:45 pm By:
Diet drug Qnexa awaits FDA approval amid safety questions http://t.co/YjlUT7Bn
Consumer Reports Warns of Lax Testing for Medical Devices - ABC News
abcnews.go.com — “Consumer Reports advises patients to do their homework before having medical devices implanted in their bodies. Companies that sell defibrillators, stents or other such products can get approval from the Food and Drug Administration without their undergoing rigorous testing, Consumer Reports warned in a new report. The FDA collects information on medical device malfunctions that lead to death. Data highlighted by Consumer Reports show 686 deaths from 2009 to last year connected to automate” View full resource at abcnews.go.com
Most Recently Shared on March 29, 2012 at 7:39 pm By:
HealthIT Policy Health IT and Health News
Consumer Reports Warns of Lax Testing for Medical Devices: Consumer Reports advises patients to do their homewor... http://t.co/z5sM68RZ
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 28, 2012 at 6:19 pm By:
Daniel Kraft Physician, Doctor, Pediatrician, Internist, and Health Executive
NYTimes: F.D.A. Approves New Anemia Drug http://t.co/WJKYbgWZ
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 28, 2012 at 1:16 am By:
FDA Approves New Anemia Drug http://t.co/Auh0ppSW
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 27, 2012 at 7:30 pm By:
HealthTrendster Health Executive
F.D.A. Approves New Anemia Drug - A new anemia drug provides a less expensive alternative for dialysis patients and ... http://t.co/9YfRzcyE
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The F.D.A. approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 27, 2012 at 7:15 pm By:
F.D.A. Approves New Anemia Drug: A new anemia drug provides a less expensive alternative for dialysis patients a... http://t.co/4Ku4AF4F
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 27, 2012 at 6:27 pm By:
Anas Younes, M.D. Doctor, Internist, Oncologist, and Physician
F.D.A. Approves Affymax's new drug Omontys for anemic patients receiving kidney dialysis... http://t.co/2o68syVQ
Amgen Loses Monopoly on Drug for Dialysis Patients - NYTimes.com
nytimes.com — “The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen’s 24-year monopoly led by its Epogen drug.” View full resource at nytimes.com
Most Recently Shared on March 27, 2012 at 6:21 pm By:
NYT: F.D.A. Approves New Anemia Drug http://t.co/z3CAgl33
Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen | Xconomy
xconomy.com — “Affymax completed its surprising comeback today, as it won FDA clearance for its first marketed drug, a product for anemia that will be the first to rival a” View full resource at xconomy.com
Most Recently Shared on March 27, 2012 at 4:58 pm By:
Luke Timmerman Health Communicator
Update to Affymax FDA approval story, with comments from CEO John Orwin. Conf call coming later today. http://t.co/bG1ow9T0
FDA approves Teva's QNASL nasal aerosol corticosteroid
news-medical.net — “Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.” View full resource at news-medical.net
Most Recently Shared on March 26, 2012 at 7:03 pm By:
Asthma News: FDA approves Teva's QNASL nasal aerosol corticosteroid: Teva Pharmaceutical Industries Ltd. announc... http://t.co/2cZSMyF6
FDA ponders need for heart studies ahead of drug approvals; New VC fund takes shape for Scotland; - FierceBiotech
fiercebiotech.com — “@FierceBiotech: Amgen's AMG 145 cuts cholesterol by 66% in early-stage trial involving patients taking statins. Article | Follow @FierceBiotech @JohnCFierce: Merck: I paid $41 billion for Read more...” View full resource at fiercebiotech.com
Most Recently Shared on March 26, 2012 at 4:57 pm By:
Cary Byrd - eDrugSearch.com Pharma and Health Advocate
FDA ponders need for heart studies ahead of drug approvals; New VC fund takes shape for Scotland; - FierceBiotech http://t.co/bpFa4yK5
Experts challenge FDA over approval for new dose of Alzheimer's drug | Science Codex
sciencecodex.com — “Approval for a new dose of a best-selling Alzheimer's drug "breached the FDA's own regulatory standard" and has led to "incomplete and distorted messages" about the drug, warn experts on bmj.com today. In the first of a new occasional” View full resource at sciencecodex.com
Most Recently Shared on March 23, 2012 at 11:58 am By:
Sara Stein MD Doctor, Psychiatrist, and Physician
#Dementia Pharma at its worst again, distorted advertising on Aricept to get you buying the new name brand version... http://t.co/puM4CgEj
Advertisement
